Pfizer to acquire cancer drugmaker Seagen for $43bn in cash

Pfizer to acquire cancer drugmaker Seagen for $43bn in cash

American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, in a move to strengthen its position in the oncology space. With the proposed acquisition, Pfizer anticipates broadening its oncology portfolio by adding Seagen’s medicines, late-stage development programs, and antibody-drug […]

Sun Pharma launches generic of breast cancer drug Palbociclib in India

Sun Pharma launches generic of breast cancer drug Palbociclib in India

Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer. The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. Palbociclib has approval in […]

FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five

FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five

Pfizer and BioNTech have received the US Food and Drug Administration (FDA) emergency use authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine for children aged six months to four years. The shot is authorized as the third 3-µg dose in the three-dose primary series. Albert Bourla — Pfizer Chairman and CEO said: “This authorization […]

Roivant Sciences, Pfizer create new business for inflammatory disease drug

Roivant Sciences, Pfizer create new business for inflammatory disease drug

Roivant Sciences, a US healthcare company, and Pfizer have established a new Vant to develop and commercialize PF-06480605 (now RVT-3101) for inflammatory and fibrotic bowel diseases. Pfizer-developed RVT-3101 is a fully human monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A), which has been shown to modulate the place and harshness of inflammation and fibrosis […]

Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn

Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn

Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to boost its presence in rare hematology. Global Blood Therapeutics is particularly focused on developing drugs for the treatment of sickle cell disease (SCD). The company’s sickle cell disease drug Oxbryta […]

Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US

Dr. Reddy’s Laboratories launches antimuscarinic drug Toviaz generic in US

Dr. Reddy’s Laboratories has launched Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets in the US market following the approval of the US Food and Drug Administration (FDA). The product is generic of Toviaz (fesoterodine fumarate) Extended-Release Tablets of Pfizer, an antimuscarinic drug used for the treatment of certain bladder problems. According to IQVIA, the Toviaz brand […]

Pfizer to invest $95m in French specialty vaccine company Valneva

Pfizer to invest $95m in French specialty vaccine company Valneva

US pharma giant Pfizer said that it will invest $95 million in Valneva, a French specialty vaccine company, for an 8.1% stake. The two firms have signed an equity subscription agreement in this connection. Besides, they have amended the terms of their collaboration and license agreement for VLA15, a vaccine candidate for Lyme disease. Pfizer […]

Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status

Pfizer RSVpreF vaccine candidate gets another FDA breakthrough therapy status

Pfizer said that PF-06928316 (RSVpreF), its respiratory syncytial virus (RSV) vaccine candidate, has been granted breakthrough therapy designation from the US Food and Drug Administration (FDA). The breakthrough therapy designation is for the use of the vaccine candidate in the prevention of lower respiratory tract disease caused by RSV in patients aged 60 years or […]